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Although lung cancer is a common disease, its diagnosis remains poor. 
While the incidence of lung cancer has decreased in western countries, 
lung cancer rates are predicted to increase generally in Asia. Studies 
investigating the mutation patterns of Asian cases compared with 
Caucasian types, lack adequate resources. Especially, lung cancer cell 
lines that are acquired from pleural effusion exudates are rare in cell line 
models. Pleural effusions in patients with NSCLC show progressive 
status and malignant features. In our study, 28 lung cancer cell lines 
derived from pleural effusions were newly established and their cellular 
and molecular characteristics were analyzed. Representative mutations 
in BRAF, EGFR, ERBB2, FGFR4, KRAS and TP53 as well as fusions 
such as ALK, CD74 and RET genes were detected and validated. Based 
on mutation profiles, drug sensitivities to gefitinib, erlotinib and 
crizotinib were measured. Cell lines that carry target mutations to each 
drug are generally sensitive. Cell lines originating from pleural 
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effusions are relatively more resistant than cell lines derived from 
tissues that harbor similar mutation. Analysis of mutational pattern and 
drug sensitivity of these cell lines can facilitate database construction 
for case study. Expression levels of specific oncoproteins such as ERK, 
ERBB2, c-MET and PTEN were detected in our cell lines. EMT 
markers such as EpCAM, E-cadherin, N-cadherin and Vimentin were 
also detected. These 28 well characterized lung cancer cell lines 
originating from malignant pleural effusions support studies associated 
with sensitivity to anti-cancer drugs and representative mutations in 
lung cancers. the few experimental results and small patient numbers 
still limit our knowledge of the acquired resistance to crizotinib. To 
meet this need, we established crizotinib-resistant sublines. Their 
parental cell lines were derived from a pleural effusion exudate which 
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Lung cancer is one of the most common causes of cancer-related death 
worldwide, with an estimated one million deaths annually. In Korea, 
lung cancer is the most lethal disease and the third common cancer. 
Although there are several other types, non-small cell lung carcinoma 
(NSCLC) constitutes about 85% of lung cancers (1,2). A number of 
driver gene mutations have been found, including epidermal growth 
factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) fusion 
with other domains, yet numerous other genetic alterations remain 
undefined (3). Aside from driver mutations, various other gene 
mutations determine the response of lung cancer cells to anti-cancer 
drugs. For instance, mutations in KRAS are known to induce resistance 
to tyrosine kinase inhibitors targeting EGFR (1,4). These complexities 
emphasize the need for more biological tools to investigate the 
functional roles of genetic alterations and their potential effect on 
clinical outcomes. Specifically, lung cancer cells which evade the 
pleural cavity have been reported to show more aggressive behavior 
than primary tumor cells (5,6). Nevertheless, the characteristics of lung 
cancer cells derived from pleural effusion exudates make them 
controversial biologic models. In this study, 28 lung cancer cell lines 
acquired from a pleural effusion exudate were established and 
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characterized with regard to the association between gene mutations and 
drug responses.  
ALK-positive lung cancer patients are treated with the ALK inhibitor, 
crizotinib. Even though the initial response of ALK-positive lung 
cancer to crizotinib is notable, acquired resistance eventually develops 
in most patients (7,8). There are several reported mechanisms to the 
resistance, including ALK amplification (9), EGFR or c-KIT activation 
(10), and the acquisition of KRAS mutations (11). Nevertheless, the few 
experimental results and small patient numbers still limit our knowledge 
of the acquired resistance to crizotinib. To meet this need, we 
established crizotinib-resistant sublines. Their parental cell lines were 
derived from a pleural effusion exudate which was thought to be more 
aggressive and resistant to anti-cancer drugs.  
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2. Materials and Methods 
 
2.1. Establishment and maintenance of human NSCLC cell lines 
Cell lines from pathologically proven Non-small-cell lung cancers were 
established. 28 pleural effusion exudate samples are obtained from 
patients in Seoul national university hospital. Cells from malignant 
pleural effusion of lung were gathered by centrifuging the medium. 
Gathered cells were then seeded into T-75cm2 flasks. Tumor cells were 
initially cultured in Opti-MEM I (Thermo Fisher Scientific, MA, USA) 
supplemented with 5% fetal bovine serum. Confined-area trypsinization 
or scraping method was used to attain a pure tumor cell population when 
stromal cells like mesothelial cells or fibroblasts grew in the initial 
culture. Established cell lines were sustained in RPMI 1640 medium 
with 10% fetal bovine serum and 1% (v/v) penicillin and streptomycin 
(10,000U/ml). Cultures were maintained in humidified incubators at 
37°C in an atmosphere of 5% CO2 and 95% air. The initial passage was 
assigned when substantial tumor cell growth was detected, and 
successive passages were given at sub-confluence after trypsinization. 
When one culture population contains both floating and adherent cells, 
floating cells were gathered by centrifuging the medium and dispersed 
by pipetting. Established cell lines were deposited to the Korean Cell 
４ 
 
Line Bank (Seoul, Korea) 
2.2. Growth properties and morphology in vitro 
To acquire each tumor population’s doubling time, 5x104 to 2x105 
viable cells from each cell line were seeded into 12–24 identical well of 
96 well plate and cell viability was calculated daily for 7-14 days. Since 
the first cell seeding, in every 24 hours, 10ul EZ-Cytox solution (Daeil 
Lab, Seoul, Korea) was added to well of each seeded lung cancer cells 
in triplicate. After 2 hour-incubation at 37 °C, Optical density of EZ-
Cytox-treated cells was calculated by Multiskan™ GO Microplate 
Spectrophotometer (Thermo Fisher Scientific, MA, USA). Growth rate 
values were measured by GraphPad Prism 5 (GraphPad Software, CA, 
USA). Growth rates are values to multiply 10 by days that cell 
population were duplicated. To observe cell line’s morphology, each 
cell line was cultured in 75cm2 culture flasks and then pictured daily by 
phase-contrast microscopy. Mycoplasma contamination was checked 
by the 16S-rRNA-gene-based polymerase chain reaction (PCR) 
amplification method using e-Myco Mycoplasma PCR Detection Kit 
(Intron Biotechnology, Gyeonggi, Korea). 
 
2.3. Genomic DNA extraction and DNA fingerprinting analysis 
Genomic DNA (gDNA) extraction was performed by using QIAamp 
DNA Mini kit (Qiagen). gDNA extracted from each lung cancer cell 
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line was amplified using an AmpFlSTR identifiler Polymerase Chain 
Reaction (PCR) Amplification Kit (Applied Biosystems, CA, USA). A 
single cycle of PCR amplified 15 short tandem repeat markers 
(CSF1PO, D2S1338, D3S1358, D5S818, D7S820, D8S1179, D13S317, 
D16S539, D18S51, D19S433, D21S11, FGA, TH01, TPOX and vWA) 
and an Amelogenin gender-determining marker containing highly 
polymorphic microsatellite markers. Amplified PCR products were 
analyzed by an ABI 3500XL Genetic analyzer (Applied Biosystems).  
 
2.4. RNA extraction and Reverse Transcriptase (RT)-PCR 
To obtain RNA, TRIzol (ambion by Invitrogen, CA, USA) was added 
to cell pellet acquired from cultured lung cancer cell line. After cell lysis 
was happened, chloroform was added. Then, the sample was vortexed 
and 4˚C, 12,000 g centrifugation. Each tube containing the sample was 
divided into aqua phase, interphase, and organic phase. In those aqua 
phase was transferred into new tube. Isopropanol alcohol was mixed 
with an equal part of the aqua phase. Mixed sample was centrifuged at 
4˚C, 12,000 g after incubated at -20˚C. RNA was acquired from pellet. 
The pellet was precipitated by ethanol. RNA was melted in 4th Distilled 
water containing RNase inhibitor (DEPC). Complementary DNA 
(cDNA) was synthesized from extracted RNA by reverse transcription 
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kit (Qiagen, MD, USA). Generally measured concentration of RNA was 
adjusted to 1ug diluted with gDNA wipeout buffer. Extracted RNA 
concentration was measured nano-spectrometer (Thermo Fisher 
Scientific, MA, USA). Each 1ug RNA was mixed with RT buffer, RT 
primer mix, and RTase. Those compounds were heated 42 ˚C for 30-45 
min purposed on annealing, extension. Heated compound was 
additionally heated 95˚C for 3 min to denature synthetic cDNA. 
 
2.5. Polymerase Chain Reaction (PCR) and mutation analysis 
cDNA acquired from lung cancer cell lines was performed by the PCR 
system 9700 (Applied Biosystems) using PCR kit (Intron 
biotechnology). To detect genome rearrangement and mutation, these 
primers sequences are summarized in Table 1.(12,13) PCR products 





Table 1. Used primer sequences 
  Forward primer Reverse primer Annealing temperature 
KIF5B exon 15 - RET exon 12 fusion TAAGGAAATGACCAACCACCAG 
GAATTTGGAAAAGTGGTCAAGG 60℃ 
KIF5B exon 16 - RET exon 12 fusion GTGAAACG GTGAAACGTTGCAAGCAGTTAG 
EML4 exon 6 - ALK exon 20 fusion GCATAAAGATGTCATCATCAACCAAG 
TCTTGCCAGCAAAGCAGTAGTTGGCAGTAGT 
60℃ 
EML4 exon 13 - ALK exon 20 fusion GTGCAGTGTTTAGCATTCTTGGGG 
EML4 exon 18 - ALK exon 20 fusion GTGGTTTGTTCTGGATGCAGAAACCAGAGATCT 63℃ 
EML4 exon 20 - ALK exon 20 fusion GGACATTCCAGCTACATCACACAC 61℃ 
CD74 exon 5 - ROS1 exon 34 fusion CCTGAGACACCTTAAGAACACCA TGAAACTTGTTTCTGGTATCCAA 57℃ 
EGFR exon 19 deletion TTGTGGAGCCTCTTACACCC AGCAGGTACTGGGAGCCAAT 60℃ 
EGFR c.2602T>G (p.L858R)  ATGTCCGGGAACACAAAGAC CATCCAGCACTTGACCATGA 60℃ 
KRAS exon1 codon12-13 TGACTGAATATAAACTTGTGGTAGTTG TCGTCCACAAAATGATTCTGAA  59℃ 
BRAF c.1799T>A (p.V600E)  TTGCATCTAAGAGGAAAGAT GGCCAAAAATTTAATCAGTG 61℃ 
ERBB2 c.1963A>G (p.I655V) GCACCCACTCCTGTGTGGAC TGCCAAAAGCGCCAGATCCA 62℃ 
FGFR4 c.1162G>A (p.G388R)  c.991C>T 
(p.Q331*) 
CGAGGCCAGGTATACGGACA CAAAGGCCTCTGCACGTACT 63℃ 
TP53 exon4  TCCCCTGCCCTCAACAAGAT AACCTCCGTCATGTGCTGTG 60℃ 
TP53 exon7 CTGGTGGTGCCCTATGAGCC AGGAGCTGGTGTTGTTGGGC 61℃ 
TP53 exon8 CCTCTTTCCTAGCACTGCCC CAAATGCCCCAATTGCAGGT 60℃ 
ALK kinase domain GGAGGTGTATGAAGGCCAGG TCGGAGGAAGGACTTGAGGT 61℃ 
ALK kinase domain  
(S1206Y, G1269A mutation target) 
ACCTCAAGTCCTTCCTCCGA CACTTAACTGGCAGCATGGC 61℃ 
ROS1 kinase domain CTGCCTTCCCTCGGGAAAAA GCTGCCAGATCCCTGTGAAT 63℃ 
β-actin GACCACACCTTCTACAATGA GCATACCCCTCGTAGATGGG 60℃ 
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2.6. CCP analysis, targeted gene sequencing  
CCP (Comprehensive Cancer Panel) is technology using Ion Ampliseq 
(Thermofisher Scientific). CCP panel could detect 409 genes mutations 
on exomes. There are various mutation types about driver-genes. 
According to the manufacturer’s instructions as described, gDNA was 
extracted from cell pellet specimen using QIAamp DNA Mini kit. 
Quantity and quality of obtained DNA samples was evaluated using the 
Qubit fluorometer and the Qubit dsDNA HS assay kit (Life 
Technologies, Gent, Belgium). AmpliSeq library was assembled with 
NEBNext®  Ultra DNA Library Prep Kit for Illumina (NEB #E7370S/L) 
and the Ion AmpliSeqTM Library Kit 2.0 (Life Technologies, Part 
#4480441 Rev. 5.0). And then, the amplicons were purified with 
AMPure XP reagent (Beckman Coulter, Brea, CA, USA). The products 
were processed in end repair by NEBNext®  End Prep kit (NEB 
#E7442). NEBNext®  Multiplex Oligos for illumina (NEB #E7335 or 
NEB #E7500) were ligated with DNA ligase. Adapter-ligated products 
were then purified by AMPure XP reagent (Beckman Coulter, Brea, CA, 
USA), and PCR-amplified for a total of 7 cycles. The complete library 
was purified by AMPure XP reagent (Beckman Coulter) and GeneRead 
size selection kit(Qiagen). Size and concentration of the library were 
analyzed by Agilent 2100 BioAnalyzer and Agilent BioAnalyzer DNA 
High-Sensitivity LabChip (Agilent Technologies). The amplified 
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libraries’s quality was proved by capillary electrophoresis (Bioanalyzer, 
Agilent). Qualified libraries were mixed in index tagged in equimolar 
amounts of the pool, after QPCR that was taken by using SYBR Green 
PCR Master Mix (Applied Biosystems). Sequencing was completed 
using an Illumina NextSeq 500 system following referred protocols for 
2x150bp sequencing. 
 
2.7. Drug sensitivity test 
2x105 to 4x105viable cells from each cell line were seeded into well 
of 96 well plate in triplicate to measure drug sensitivity of Crizotinib, 
Erlotinib, and Gefitinib. A day after, all cell lines was respectively 
treated for proper concentration of Crizotinib, Erlotinib, and Gefitinib. 
If the cell line was adherent cell, adherent state was confirmed. After 72 
hours-incubation at 37 °C, 10ul EZ-Cytox solution was added to well 
of each seeded lung cancer cells. After 2 hour-incubation at 37°C, 
optical density of EZ-Cytox-treated cells was calculated by 
Multiskan™ GO Microplate Spectrophotometer (Thermo Fisher 
Scientific). These steps were repeated in triplicate. The half maximal 
effective concentration (EC50) were measured by GraphPad Prism 5 
(GraphPad Software). 
 
2.8. Protein extraction and Western blotting 
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Cultivated cells that had full confluency were harvested with cell 
scrapper. Cell pellet was treated by EzRIPA buffer (ATTO Co., Tokyo, 
Japan) after washed by cool PBS. Whole protein was extracted by this 
step. Protein concentration of each cell line was determined by SMART 
micro BCA protein assay kit (Intron biotechnology). Proteins that fixed 
into equal concentration were loaded on a 4-12% Bis-Tris gel 
(Invitrogen) at 70 volts for 3 hours and then proteins on loaded gel were 
transferred to a PVDF membrane (Invitrogen) by electro-blotting in 
condition under a constant current of 80mA at 4 °C overnight. Proteins 
of transferred membrane was blocked by incubating in 1.5% to 2.0% 
skim milk and 0.05% Tween 20-TBS buffer including 1mM MgCl2 for 
an hour at room temperature. Primary antibodies were used against 
EGFR, exon 19 E746-A750 deleted EGFR, ERK1, ERK2, pERK1/2, 
PTEN, c-MET, EpCAM, E-cadherin, N-cadherin and Vimentin and -
actin. Those antibodies were Abcam products (Abcam, Cambridge, UK) 
except for exon 19 E746-A750 deleted EGFR that was Cell signaling 
product (Cell signaling, MA, USA). Mouse or rabbit IgG 2nd antibody 
(Jackson Immunoresearch, PA, USA) (1:5000) conjugated with 
peroxidase that matched with used 1st antibody was added to membrane. 
After chemiluminescent working solution, WESTZOLTM (Intron 
biotechnology) was treated to the membrane, the membrane was 




Cells were seeded on chambered coverglass (Thermo Fisher Scientific, 
MA, USA) with a desirable cell confluency. The chambered coverglass 
was designed to be hydrophilic and no ECM component was treated 
before seeding. 72 hours after cell seeding, cells were washed with cold 
DPBS for 15 minutes three times. Then, cells were fixed and 
permeabilized with BD Cytofix/Cytoperm™ (BD science, CA, USA). 
After cells were washed with washing solution (BD science), DPBS 
containing 2% FBS (GE Healthcare Life Sciences, Buckinghamshire, 
UK) was applied for an hour for blocking. After cells were washed with 
cold DPBS, DKK1 (Santa Cruz Biotechnology, CA, USA) and β-catenin 
antibody (Abcam, Cambridge, United Kingdom) diluted in 0.05% of 
PBS.T was applied for an 1.5 hours in room temperature. Thereafter, 
cells were washed with 0.05% of PBS.T, and Alexa 488 and Alexa 568 
secondary antibodies (Thermo Fisher Scientific, MA, USA) diluted in 
0.05% of PBS.T were applied for an hour in room temperature. 1x DAPI 
and Rhodamine-conjugated Phalloidin (Sigma-Aldrich, MO, USA) were 
diluted in distilled water and applied for 30 minutes in room temperature. 
The cells were washed with DPBS three times, and pictured under 
confocal microscope. LSM800 Confocal Laser Scanning Microscope 
and ZEN software (Carl Zeiss, Oberkochen, Germany) was used to 
examine cells. Diverse magnifications were used for different growth 
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patterns and sizes of cells. The intensity of each channel was fixed for 
the comparison of target protein expression between samples. Digital 
resolution, scan speed and the number of pictures averaged were set to 
1024 x 1024, 40 seconds per one channel, and 8 pictures respectively. 
The pictures were focused on the very bottom of the fixed cells for 
investigating protruding region of cell colonies and the location of DKK1 
and β-catenin.  
 
2.10. RNA and Direct Sequencing 
Total RNA was isolated from cell lysate using Trizol (Qiagen) and 
Qiagen RNeasy Kit (Qiagen). Sequencing libraries were prepared using 
the Illumina TruSeq Stranded Total RNA Library Prep Kit. Fifty-one 
million reads were obtained from the cell lysates. Following base-calling 
and alignment with the Tuxedo Suite, rejected reads were analyzed using 
FusionMap, ChimeraScan, and Defuse with default parameters for RNA 
and alignment to GRCh37.72. The output was filtered to include in-
frame fusions, with at least one rescued read and two unique seed reads, 
and exclude known, recurrent artifacts. Sequencing of RNA isolated 
from early onset colorectal cancer cell lines was used to identify RNA 
sequences that spanned two different regions in a chromosome.  
 
2.11. Whole Exome Sequencing 
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SureSelect sequencing libraries were prepared according to 
manufacturer’s instructions (Agilent sureselect all Exon kit 50 Mb) 
using the Bravo automated liquid handler. Three micrograms of 
genomic DNA were fragmented to a median size of 150 bp using the 
Covaris-S2 instrument (Covaris, Woburn, MA). The adapter ligated 
DNA was amplified by PCR, and the PCR product quality was assessed 
by capillary electrophoresis (Bioanalyzer, Agilent). The hybridization 
buffer and DNA blocker mix were incubated for 5 minute at 95°C and 
then for10 minutes at 65°C in a thermal cycler. The hybridization 
mixture was added to the bead suspension and incubated for 30 minutes 
at RT while mixing. The beads were washed, and DNA was eluted with 
50 ml SureSelect elution buffer (Agilent). The flow cell loaded on 
HISEQ 2500 sequencing system (Illumina). 
 
2.12. Establishement of crizotinib-resistant lung cancer cell lines  
We established two crizotinib-resistant sublines (SNU-2550CR and 
SNU-2563CR), derived from the parental SNU-2550 and SNU-2563 
cell lines by continuously exposing them to 5μ of crizotinib for 90 days.  
 
2.13. Statistical analysis 
Statistical analysis was performed using R program version 3.3.1 (R 
Foundation for Statistical Computing, Vienna, Austria) with various 
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packages including maftools, PerformanceAnalytics, survminer, 
survival, iplot, gplot, and lattice. The relationship between gene 
mutation or expression and clinical data of pancreatic adenocarcinoma 
was analyzed by the Chi-square test and Pearson correlation method. 
Fisher’s exact test was used to analyze GO analysis of various genes. 
All tests were performed using bilateral 95% confidence intervals (CI). 


















3. Results  
3.1. Culture characteristics 
The in vivo information for patient SNU-2612A was reported 
previously. (12) The general in vivo information of the cell lines are 
summarized in Table 2. The morphologies of the established cell lines 
were categorized into four types: polygonal, oval, fibroblast-like, and 
round (Figure 1, Table 3). Two cell lines (SNU-2708.1 and SNU-3023) 
formed floating and adherent aggregates exhibiting round morphologies. 
Even though the cells were derived from a lung pleural effusion exudate, 
which was expected to have resistance to anoikis and to form floating 
aggregates, only two cell lines maintained the floating nature. This 
observation may explain the mechanism of how cells invade the lung 
pleural cavity. The growth rate of SNU-2708.1 could not be measured 
due to its aggregate growth pattern and slow growth. The culture 
conditions for SNU-2708.1 might not be adequate for the SNU-2708.1 
cell line. DNA fingerprinting revealed a heterogeneous distribution of 
15 tetranucleotide repeat loci and an Amelogenin gender determining 
marker in each cell line. It confirmed 28 unique and unrelated cell lines, 
without cross-contamination (Table 4). All cell lines were confirmed to 






Figure 1. Phase-contrast microscopy of newly established 28 SNU lung 
cancer cell lines. Scale bar in microscopy of SNU-2681 represent 50μm and 






Table 2. Origin and in vivo characteristics of 28 SNU human lung 





Origin Sex Age Pathology 
1 SNU-2535 2010-11-10 
pleural 
effusion 
F 56 ADC 
2 SNU-2550 2011-02-21 
pleural 
effusion 
F 35 ADC 
3 SNU-2553 2011-03-11 
pleural 
effusion 
M 40 ADC 
4 SNU-2556 2011-03-29 
pleural 
effusion 
F 72 ADC 
5 SNU-2563 2011-04-19 
pleural 
effusion 
M 49 ADC 
6 SNU-2585 2011-10-10 
pleural 
effusion 
M 75 ADC 
7 SNU-2588 2011-10-26 
pleural 
effusion 
M 43 ADC 
8 SNU-2589 2011-10-27 
pleural 
effusion 
F 52 ADC 
9 SNU-2606 2012-03-07 
pleural 
effusion 
F 51 ADC 
10 SNU-2612A 2012-03-23 
pleural 
effusion 
M 33 ADC 
11 SNU-2627 2012-06-05 
pleural 
effusion 
F 46 NOS 
12 SNU-2637 2012-09-06 
pleural 
effusion 
M 42 ADC 
13 SNU-2641 2012-09-24 
pleural 
effusion 
M 64 NOS 
14 SNU-2643 2012-09-27 
pleural 
effusion 
F 57 NOS 
15 SNU-2657 2012-11-27 
pleural 
effusion 
F 70 ADC 
16 SNU-2681 2013-03-05 
pleural 
effusion 
M 63 ADC 
17 SNU-2689 2013-03-21 
pleural 
effusion 
F 74 ADC 
18 SNU-2693 2013-04-11 
pleural 
effusion 
M 60 ADC 
19 SNU-2708.1 2013-06-10 
pleural 
effusion 
M 56 ADC 
20 SNU-2727 2013-07-08 
pleural 
effusion 
F 39 ADC 
21 SNU-2741 2013-08-19 
pleural 
effusion 
M 57 ADC 
22 SNU-2749 2013-09-25 
pleural 
effusion 
M 67 ADC 
23 SNU-2778 2013-12-11 
pleural 
effusion 
M 54 ADC 
24 SNU-2832 2014-03-05 
pleural 
effusion 
F 58 ADC 
25 SNU-2867 2014-04-11 
pleural 
effusion 
M 57 ADC 
26 SNU-2887 2014-05-20 
pleural 
effusion 
F 56 ADC 
27 SNU-2964 2014-09-03 
pleural 
effusion 
F 78 ADC 
28 SNU-3023 2014-12-04 
pleural 
effusion 
F 70 ADC 
*ADC : adenocarcinoma 
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Table 3. in vitro characteristics of 28 SNU human lung cancer cell lines 
 




1 SNU-2535 Adherent 61 Polygonal 
2 SNU-2550 Adherent 32 Oval 
3 SNU-2553 Adherent 61 Fibroblast-like 
4 SNU-2556 Adherent 35 Oval 
5 SNU-2563 Adherent 47 Polygonal 
6 SNU-2585 Adherent 31 Oval 
7 SNU-2588 Adherent 39 Polygonal 
8 SNU-2589 Adherent 33 Polygonal 
9 SNU-2606 Adherent 28 Oval 
10 SNU-2612A Adherent 39 Fibroblast-like 
11 SNU-2627 Adherent 40 Polygonal 
12 SNU-2637 Adherent 30 Polygonal 
13 SNU-2641 Adherent 44 Oval 
14 SNU-2643 Adherent 27  Polygonal 
15 SNU-2657 Adherent 27 Polygonal 
16 SNU-2681 Adherent 34 Round / Polygonal 
17 SNU-2689 Adherent 25 Fibroblast-like / Oval 
18 SNU-2693 Adherent 34 Polygonal / Oval 
19 SNU-2708.1 floating -  Round 
20 SNU-2727 Adherent 102  Polygonal 
21 SNU-2741 Adherent 55 Polygonal 
22 SNU-2749 Adherent 31 Polygonal 
23 SNU-2778 Adherent 35 Polygonal 
24 SNU-2832 Adherent 25 Fibroblast-like 
25 SNU-2867 Adherent 87 
Fibroblast-like / 
Polygonal 
26 SNU-2887 Adherent 102 Polygonal 
27 SNU-2964 Adherent 46 Polygonal 




Table 4. DNA fingerprinting analysis using 16 STR loci for newly 
established 28 SNU human lung cancer cell lines 
 
No. Cell-Name D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S317 D16S539 
1 SNU-2535 13,15 28,29 11 11 14,15 7,9.3 9,11 9,11 
2 SNU-2550 14,15 29,30 8,12 10 15 9 8,11 9 
3 SNU-2553 12,13 30.2,31 9,11 11,12 16 7 8 11 
4 SNU-2563 11,15 28,29 10,11 10 15 7,9.3 11,13 12,13 
5 SNU-2556  11,14 29,32.2 9,10 10,11 16 9 12,13 9 
6 SNU-2585 12,16 31,31.2 10,12 12 16 7 9,10 9,12 
7 SNU-2588 10,13 32.2 10,12 10,11 17 7,9 8,12 12 
8 SNU-2589 14,16 30 8,12 12,13 15 6,8 11,12 9 
9 SNU-2606 13 29 9,12 12,13 15 7,9 9 8,9 
10 SNU-2612A 13,14 30 8,10 10 15,16 9 8,12 9,13 
11 SNU-2627 10,11 30,32.2 10,11 12,13 17 7,9 12 12 
12 SNU-2637 12,13 30,31.2 8,9 9,13 16,17 9 9,11 9 
13 SNU-2641 13 30,31.2 11,13 12,13 15 9 8,10 10,13 
14 SNU-2643 13 29,31 8,11 10,12 15,17 6,7 8 12 
15 SNU-2657 10,12 29 9,10 11,12 14 6,7 8 9,12 
16 SNU-2681 11,12 29.2,30 11 10,12 15 9 10 12 
17 SNU-2689 11,14 30 11 12,14 15,17 6 11 9 
18 SNU-2693 14,15 29,30 8,10 10 15,18 9 13 11,12 
19 SNU-2708.1 14 29,30 8,10 10,11 18 9 11 9,12 
20 SNU-2727 11 29,31.2 11,14 10 16 6,8 9 9 
21 SNU-2741 14 30,32.2 8,12 9,12 15 7,9 8 9,11 
22 SNU-2749 14 30 9,12 12 16,17 6,7 10,12 10,12 
23 SNU-2778 13,16 32.2 12 10,11 15,17 8 8 9,10 
24 SNU-2832 15,16 30,31 8,11 7,11 15,19 6 10,11 9,13 
25 SNU-2867 15 29,30 9,10 12 15,16 6,9 8,11 9 
26 SNU-2887 13 29,31 10,11 12 17 7 12 10 
27 SNU-2964 13,15 29.2,30 10,11 10,12 15,16 7,9 12 9,11 







No. Cell-Name D2S1338 D19S433 Vwa TPOX D18S51 Amelogenin D5S818 FGA 
1 SNU-2535 20,23 10.2,14 16,17 11 15 X 10,12 24,27 
2 SNU-2550 23,24 12,15,15.2 14,18 11 8,17 X 11,12 19 
3 SNU-2553 OL,23 13,14 14,15 8,9 16 X,Y 9,11 21,24 
4 SNU-2563 18,23 13.2,15 17,18 8,11 15 X,Y 10,11 22,23 
5 SNU-2556  20,26 14,14.2 14 8,11 15 X,Y 11 23,24 
6 SNU-2585 19,20 13 18 8,9 13,18 X,Y 10,11 22 
7 SNU-2588 24,25 13.2,15 18 8 13,17 X,Y 11,13 24 
8 SNU-2589 17,20 13,17.2 17 8,11 13,14 X 11,12 21,22 




19,21 13,14 18 8,10 13,16 X,Y 9 18,21 
11 SNU-2627 25 13,14.2 17,19 8,11 21 X 11,12 OL 
12 SNU-2637 18,23 14.2,15.2 18,19,20 8 13,21 X,Y 11 22,25 
13 SNU-2641 17,23 13 16,17 8,11 14,15 X,Y 11 17,21 
14 SNU-2643 19,24 13.2,15 14,17 8,11 20 X 11 22,24 
15 SNU-2657 24 13,15 16 11,12 13,22 X 11,12 22,23 
16 SNU-2681 17,23 14,15.2 17 8 13 X,Y 9,10 21 
17 SNU-2689 22 14.2,15.2 17 11 14,17 X 10,11 20 




24 14 17 9 17 X,Y 11 20,23 
20 SNU-2727 19 13,14 14 8 17 X 11 23 
21 SNU-2741 23 10.2,14 17 8 14 X 10,11 22 
22 SNU-2749 18 13,14 14,18 8,11 12 X,Y 11 22,23 
23 SNU-2778 23,26 14,15.2 14 8 20 X 10,12 22,23 
24 SNU-2832 18,24 14 14 8 14,15 X 11,12 21,22 
25 SNU-2867 23 13,14 20 11 16 X,Y 11 24 
26 SNU-2887 23 16.2 18 8 14 X 11 24,25 
27 SNU-2964 17 14 17 8,9 16 X 9,12 21,22.2,23.2 




Figure 2. Mycoplasma test by the 16S-rRNA-gene-based polymerase 
















3.2. Mutational traits 
To investigate the representative genetic aberrations in the newly-
established NSCLC cell lines, targeted gene sequencing was performed. 
The mutation profiles of six genes involved in drug responses are 
summarized in Table 5. When the detected mutation had been already 
reported in the Clinvar database (https://www.ncbi.nlm.nih.gov/clinvar), its 
predicted effect was specified. The effect of an EGFR R521K 
polymorphism was listed as benign in the Clinvar database. However, 
several studies indicated its association with the occurrence of colorectal 
cancer (14) and the response to cetuximab in lung cancer (15). Since 
targeted sequencing may omit large deletions, direct Sanger sequencing was 
performed on six genes (BRAF, EGFR, ERBB2, FGFR4, KRAS, and TP53) 
(Figure 3). Although targeted gene sequencing has revealed the presence of 
previously reported oncogenic mutations, a few significant oncogenes and 
tumor suppressor genes, such as KMT2D, RBM10, and U2AF1, were not 
included. To establish more a comprehensive mutational context, whole 
exome sequencing (WES) was performed. The general information, 
including variant classifications and SNV classes, are summarized in Figure 
4a. SNU-2832 had the largest number of variants, whereas SNU-2612A had 
the smallest number of variants. The median number of variants per sample 
was 244. Mutational load and the response to checkpoint immunotherapy 
have been closely associated in colorectal and lung cancer. Environmental 
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factors, such as UV radiation or smoking, or germline mutations in the 
mismatch repair genes affect the hypermutation rate in tumors (16). We 
analyzed the exclusive mutations in the hyper-mutated and hypo-mutated 
groups (Figure 5). The mutational signatures, characterized by a specific 
pattern of nucleotide substitutions, were extracted by decomposing a matrix 
of nucleotide substitutions, then comparing them to the public database 
presented by Alexandrov et al. The newly-established lung cancer cell lines 
showed a pattern of signature 5 (Figure 4b). Since the signature 5 pattern 
doesn’t have specific etiology, we visualized the p-values of the top 30 
signatures (Figure 4c). Signature 6 had similar p-values as signature 5. 
Signature 6 is associated with high numbers of small (shorter than 3bp) 
insertions and deletions at mono/polynucleotide repeats. It is associated 
with defective DNA mismatch repair and is found in microsatellite unstable 
tumors. The prevalence of aberrations in key driver genes including fusion 
genes is shown in Figure 4d and Figure 6. All cell lines were verified by 
PCR and targeted gene sequencing according to representative genetic 
variations in NSCLC (Table 6) (3,17). Cell lines carrying fused genes were 
confirmed by PCR using specific primer sets targeting break junctions. 
SNU-2535, SNU-2550, SNU-2553, SNU-2563, and SNU-2637 carried an 
EML4-ALK fusion. Cell lines carrying an EML4-ALK fused gene showed 
no mutation in the ALK kinase domain, with the exception of SNU-2535, 
which carried a G1269A mutation in the kinase domain (Figure 7). In 
24 
 
contrast, SNU-2606 and SNU-2832 carried a CD74-ROS1 fusion. The 
expression of ALK and the ROS1 kinase domain were detected by RT-PCR 
(Figure 8). Further, SNU-2612A and SNU-2778 harbored a RET fusion 
gene. Standing mutations were also detected by targeted gene sequencing 
of each cell line. The mutational statuses and proposed functions of such 
genes are summarized in Table 7. Many such driver genes in cancer co-
occur or show exclusiveness in their mutation patterns. We performed pair-
wise Fisher’s exact test to detect such significant pairs of genes. For instance, 
mutations in the KRAS and TSC1 genes were co-occurring (Figure 4e). 
Mutations were further analyzed for gene set enrichment analysis to find 
representative aberrant pathways in the established lung adenocarcinoma 
cell lines. Genes of the MAPK family signaling cascade and transcriptional 
regulation by TP53 were mostly mutated (Figure 4f). In association with the 
aberrant pathway analysis, we also predicted which pathway could be 
targeted by drugs. The results showed that kinase and the DNA repair 
pathways were potential drug gene categories (Figure 4g). Other mutations, 
such as specific protein over-expression related to drug sensitivity, were 
detected by Western blotting, including EGFR, ERK1/2, PTEN, and c-MET 
(Figure 9). The EGFR protein was highly expressed in SNU-2589, SNU-
2606, SNU-2681, SNU-2693, SNU-2708.1, SNU-2727, SNU-2741, SNU-
2867, and SNU-2964. The EGFR protein expression of SNU-2606 was the 


































nt change  
(a.a. change) 
effects nt 
nt change  
(a.a. change) 
effects 
SNU-2535 wt   1591 aGg>aAg(R521K) Benign 
SNU-2550 wt   1591 aGg>aAg(R521K) Benign 
SNU-2553 wt   wt   
SNU-2556 wt   1591 aGg>aAg(R521K) Benign 
SNU-2563 wt   1591 aGg>aAg(R521K) Benign 
SNU-2585 wt   
1591 aGg>aAg(R521K) Benign 
1611 Aat>Gat(N528D) - 
SNU-2588 wt   1591 aGg>aAg(R521K) Benign 
SNU-2589 wt   
1591 aGg>aAg(R521K) Benign 
2053 cGg>cAg(R675Q) - 
SNU-2606 wt   1591 aGg>aAg(R521K) Benign 
SNU-2612A wt   wt   
SNU-2627 wt   wt   
SNU-2637 wt   wt   
SNU-2641 wt   wt   




Pathogenic 1591 aGg>aAg(R521K) Benign 
SNU-2681 wt   wt   
SNU-2689 wt   




SNU-2693 wt   1591 aGg>aAg(R521K) Benign 
SNU-2708.1 wt   
1591 aGg>aAg(R521K) Benign 








SNU-2727 wt   wt   




Pathogenic 1591 aGg>aAg(R521K) Benign 
SNU-2778 wt   1591 aGg>aAg(R521K) Benign 
SNU-2832 wt   1591 aGg>aAg(R521K) Benign 
SNU-2867 wt   1591 aGg>aAg(R521K) Benign 
SNU-2887 wt   1591 aGg>aAg(R521K) Benign 
SNU-2964 wt   1591 aGg>aAg(R521K) Benign 













nt change  
(a.a. change) 
effects nt 
nt change  
(a.a. change) 
effects 
SNU-2535 wt   1162 Ggg>Agg(G388R) Pathogenic 
SNU-2550 wt   wt   
SNU-2553 wt   wt   
SNU-2556 wt   1162 Ggg>Agg(G388R) Pathogenic 
SNU-2563 wt   wt   
SNU-2585 wt   wt   




Pharmacogenic wt   
SNU-2606 wt   1162 Ggg>Agg(G388R) Pathogenic 
SNU-2612A wt   wt   
SNU-2627 wt   1162 Ggg>Agg(G388R) Pathogenic 
SNU-2637 wt   wt   
SNU-2641 wt   wt   













1162 Ggg>Agg(G388R) Pathogenic 
1251 caG>caA(Q417Q) Splice site 
SNU-2693 wt   wt   
SNU-2708.1 wt   wt   
SNU-2727 wt   wt   
SNU-2741 wt   
1162 Ggg>Agg(G388R) Pathogenic 




Pharmacogenic 1162 Ggg>Agg(G388R) Pathogenic 




Pharmacogenic wt   
SNU-2867 wt   wt   
SNU-2887 wt   wt   
SNU-2964 wt   wt   










nt change  
(a.a. change) 
effects nt 
nt change  
(a.a. change) 
effects 
SNU-2535 wt     wt   
SNU-2550 wt   wt   
SNU-2553 wt   wt   
SNU-2556 wt   wt   




Pathogenic wt   
SNU-2588 wt   wt   
SNU-2589 wt   438 tgG>tgA(W146*) - 
SNU-2606 wt   817 Cgt>Tgt(R273C) Pathogenic 
SNU-2612A wt   wt   
SNU-2627 wt   wt   
SNU-2637 wt   wt   
SNU-2641 wt   wt   
SNU-2643 wt   818 cGt>cAt(R273H) Pathogenic 




Pathogenic 329 cGt>cTt(R110L) 
Probable-
pathogenic 
SNU-2689 wt   wt   
SNU-2693 wt   wt   
SNU-2708.1 wt   wt   
SNU-2727 wt   wt   
SNU-2741 wt   wt   
SNU-2749 wt   991 Cag>Tag(Q331*) - 
SNU-2778 wt   wt   
SNU-2832 wt   wt   
SNU-2867 wt   wt   
SNU-2887 wt   wt   
SNU-2964 wt   wt   









Figure 3. Validation of results of targeted gene sequencing by Sanger 
sequencing analysis.  
a. EGFR c.2602T>G (p.L858R) variation was detected in SNU-2689, 
SNU-2727 and SNU-3023. b. KRAS c.35G>T (p.G12V) mutation was 
validated in SNU-2585 and c.34G>T (p.G12V) was also validated in 
SNU-2681. c. BRAF c.1799T>A (p.V600E) variation was detected in 
SNU-2657 and 2749. d. TP53 c.839G>A (p.R280K) missense mutation 
that is located in exon 7 was detected in SNU-2563. In same exon, SNU-
2606 and SNU-2643 harbored pathogenic single nucleotide 
polymorphism. SNU-2606 had c.817C>T (p.R273C) mutation and 
SNU-2643 had c.818C>T (p.R273H) mutation. SNU-2589 harbored 
c.438G>A (p.W146*) nonsense mutation in exon 4. And SNU-2749 
had c.991C>T (p.Q331*) nonsense mutation in exon 8. PCR substrate 
that was used in validating Nonsense mutation was genomic DNA 
differed from other substrate that was cDNA. e. ERBB2 c.1963A>G 
(p.I655V) variation was detected in SNU-2589, SNU-2657, SNU-2681, 
SNU-2689, SNU-2749 and SNU-2832. f. Validation of results of 
FGFR4 genes mutation regions sequencing by Sanger sequencing 
analysis. FGFR4 c.1162G>A (p.G388R) mutation was detected in total 
14 cell lines of 28 cell lines (SNU-2535, SNU-2556, SNU-2563, SNU-
2588, SNU-2606, SNU-2627, SNU-2643, SNU-2657, SNU-2689, 
SNU-2741, SNU-2749, SNU-2778, SNU-2964 and SNU-3023). SNU-
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2689 was additionally c.991C>T (p.Q331*) nonsense mutation by using 





Figure 4. Mutational context of the established lung cancer cell lines. a. 
Summarization of variants. b. Mutational signatures characterized by a 
specific pattern of nucleotide substitutions. c. Visualization of p-values 
of mutational signature. d. Mutational landscape of the established lung 
cancer cell lines. e. Co-occurring or exclusiveness in the mutation 
patterns of lung cancer cell lines. f. Gene set enrichment analysis to find 
representative aberrated pathways g. Targetable genes were identified in 

























Figure 6. Fusion gene detection by PCR and validation  
a. PCR result of each fusion gene set primer. About KIF5B-RET 
rearrangement, reverse primer was RET exon 12 and then forward primer 
were KIF5B exons 15 and exon 16. Only SNU-2778 had expression of 
KIF5B exon 15-RET exon 12 and SNU-2612A had expression of KIF5B 
exon 16-RET exon 12. In EML4-ALK rearrangement, reverse primer of all 
set was ALK exon 20. Forward primers were exons 6, 13, 18 and 20 of 
EML4. SNU-2550 had EML4 exon 6-ALK fusion and SNU-2535 had 
EML4 exon 13-ALK fusion. The cell line that had EML4 exon 18-ALK 
fusion was SNU-2563 only. About EML4 exon 20-ALK fusion, SNU-2553 
and SNU-2637 had these fusions. The other fusion set, CD74-ROS1 fusion 
was detected in SNU-2606 and SNU-2832. Those cell lines have CD74 
exon 6 and ROS1 exon 34 rearrangement. To finely detect PCR result, this 
fusion forward primer was CD74 exon 5 region. b. Validation of PCR results 
by Sanger sequencing analysis of each cell line that had fusion gene 
detected by PCR 
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Table 6. Mutation profiles by targeted gene sequencing (not confirmed 
by Sanger sequencing) 
Cell line 
ATM EPHA3 ERBB4 
nt 
nt change  
(a.a. change) 
nt 
nt change  
(a.a. change) 
nt 
nt change  
(a.a. change) 
SNU-2535 wt   wt   wt   
SNU-2550 wt  wt  wt  
SNU-2553 wt  2770 Tgg>Cgg(W924R) wt  
SNU-2556 wt  wt  wt  
SNU-2563 6497 gTg>gCg(V2166A) wt  wt  
SNU-2585 wt  wt  
1744 Cat>Gat(H582D) 
  
SNU-2588 wt  wt  wt  




SNU-2606 wt  
wt  wt  
    
SNU-2612A wt  wt  wt  
SNU-2627 wt  wt  wt  
SNU-2637 wt  wt  wt  
SNU-2641 wt  2770 Tgg>Cgg(W924R) wt  
SNU-2643 4138 Cat>Tat(H1380Y) wt  wt  
SNU-2657 wt  wt  wt  
SNU-2681 wt  2770 Tgg>Cgg(W924R) wt  
SNU-2689 wt  wt  wt  
SNU-2693 wt  2770 Tgg>Cgg(W924R) wt  
SNU-2708.1 
2948 aAt>aGt(N1983S) 
wt  wt  
  
SNU-2727 wt  wt  wt  
SNU-2741 wt  wt  wt  
SNU-2749 323 gCa>gGa(A108G) wt  wt  
SNU-2778 1208 tCa>tTa(S403L) 2770 Tgg>Cgg(W924R) wt  
SNU-2832 wt  wt  wt  
SNU-2867 wt  wt  wt  
SNU-2887 wt  wt  wt  
SNU-2964 wt  2770 Tgg>Cgg(W924R) wt  







FGFR2 FGFR3 KDR 
nt 
nt change  
(a.a. change) 
nt 





SNU-2535 wt   wt   wt   
SNU-2550 wt  wt  wt  
SNU-2553 wt  wt  wt  
SNU-2556 wt  wt  1416 caA>caT(Q472H) 
SNU-2563 17 cGt>cCt(R6P) wt  wt  
SNU-2585 wt  wt  
1416 caA>caT(Q472H) 
  
SNU-2588 wt  1352 aCg>aTg(T451M) 1416 caA>caT(Q472H) 
SNU-2589 wt  wt  wt  
SNU-2606 
wt  wt  wt  
      
SNU-2612A wt  wt  2443 Gaa>Taa(E815*) 
SNU-2627 wt  wt  wt  
SNU-2637 wt  wt  wt  
SNU-2641 17 cGt>cCt(R6P) wt  wt  
SNU-2643 17 cGt>cCt(R6P) 1352 aCg>aTg(T451M) 1416 caA>caT(Q472H) 
SNU-2657 wt  wt  1416 caA>caT(Q472H) 
SNU-2681 wt  wt  wt  
SNU-2689 wt  wt  
1416 caA>caT(Q472H) 
  
SNU-2693 wt  wt  wt  




SNU-2727 wt  wt  wt  
SNU-2741 wt  1352 aCg>aTg(T451M) 1416 caA>caT(Q472H) 
SNU-2749 17 cGt>cCt(R6P) wt  1416 caA>caT(Q472H) 
SNU-2778 wt  wt  wt  
SNU-2832 wt  wt  wt  
SNU-2867 wt  wt  wt  
SNU-2887 wt  wt  1416 caA>caT(Q472H) 
SNU-2964 17 cGt>cCt(R6P) wt  wt  










NOTCH1 PAK3 PDGFRA 
nt 
nt change (a.a. 
change) 
nt 
nt change (a.a. 
change) 
nt 
nt change (a.a. 
change) 
SNU-2535 wt   wt   wt   
SNU-2550 wt  wt  wt  
SNU-2553 wt  wt  wt  
SNU-2556 wt  wt  wt  
SNU-2563 wt  wt  wt  
SNU-2585 wt  wt  wt  
SNU-2588 wt  wt  1432 Tcc>Ccc(S478P) 
SNU-2589 wt  wt  wt  
SNU-2606 
wt  wt  wt  
      
SNU-2612A wt  wt  wt  
SNU-2627 wt  wt  wt  
SNU-2637 wt  1033 Gat>Aat(D345N) wt  
SNU-2641 wt  wt  wt  
SNU-2643 wt  wt  wt  
SNU-2657 wt  wt  wt  
SNU-2681 wt  wt  wt  
SNU-2689 wt  wt  
1432 Tcc>Ccc(S478P) 
  
SNU-2693 wt  1438 Gaa>Taa(E480*) wt  
SNU-2708.1 
7174 Atg>Ctg(M2392L) 
wt  wt    
  
SNU-2727 wt  wt  wt  
SNU-2741 wt  wt  wt  
SNU-2749 wt  wt  1432 Tcc>Ccc(S478P) 
SNU-2778 wt  wt  wt  
SNU-2832 wt  wt  wt  
SNU-2867 wt  wt  wt  
SNU-2887 wt  wt  1432 Tcc>Ccc(S478P) 
SNU-2964 wt  wt  wt  









PTPRD STK11 TSC1 
nt 
nt change (a.a. 
change) 
nt 
nt change (a.a. 
change) 
nt 
nt change (a.a. 
change) 
SNU-2535 wt   1062 ttC>ttG(F354L) wt  
SNU-2550 wt  wt  wt  
SNU-2553 wt  wt  wt  
SNU-2556 wt  wt  wt  
SNU-2563 wt  wt  2075 cGa>cAa(R692Q) 
SNU-2585 wt  wt  
1335 gaA>gaG(E445E) 
965 aTg>aCg(M322T) 
SNU-2588 wt  wt  wt  
SNU-2589 wt  wt  wt  
SNU-2606 
wt  wt  1335 gaA>gaG(E445E) 
    965 aTg>aCg(M322T) 
SNU-2612A wt  wt  wt  
SNU-2627 wt  wt  wt  
SNU-2637 wt  wt  wt  
SNU-2641 5004 tgT>tgA(C1668*) wt  wt  
SNU-2643 wt  wt  wt  
SNU-2657 wt  wt  wt  
SNU-2681 wt  wt  2075 cGa>cAa(R692Q) 
SNU-2689 wt  wt  wt  
SNU-2693 wt  wt  wt  
SNU-2708.1 wt  wt  wt  
SNU-2727 wt  wt  wt  
SNU-2741 wt  wt  wt  
SNU-2749 wt  wt  wt  
SNU-2778 wt  wt  wt  





wt  wt  
      
SNU-2887 wt  wt  wt  
SNU-2964 wt  wt  wt  






Figure 7. Validation of ALK mutation in SNU-2535. Sanger sequencing 
to ALK kinase domain. Cell lines that have EML4-ALK fused gene don’t 
have any mutation in ALK kinase domain except for SNU-2535 in our 








Figure 8. Expressions of ALK and ROS1 kinase domain by RT-PCR. 
SNU-2535, SNU-2550, SNU-2553, SNU-2563, SNU-2589, SNU-2627 
and SNU-2637 had expression of ALK kinase domain in mRNA levels. 
Specifically, SNU-2563, SNU-2589 and SNU-2637 were overexpressed, 
despite SNU-2589 didn’t have EML4-ALK fused gene. SNU-2553, 
SNU-2589, SNU-2606, SNU-2637 and SNU-2832 had high expression 





Table 7. Summary of mutations by Sanger sequencing in each cell line 
 
No.  Cell-Name Data 
1 SNU-2535 EML4(exon13)-ALK(exon20) fusion, FGFR4 G388R, ALK G1269A 
2 SNU-2550 EML4(exon6)-ALK(exon20) fusion 
3 SNU-2553 EML4(exon20)-ALK(exon20) fusion 
4 SNU-2556 EGFR exon19 deletion, FGFR4 G388R 
5 SNU-2563 EML4(exon18)-ALK(exon20) fusion, TP53 R280K 
6 SNU-2585 KRAS G12V 
7 SNU-2588 FGFR4 G388R 
8 SNU-2589 ERBB2 I655V, TP53 W146* nonsense mutation 
9 SNU-2606 CD74(exon6)-ROS1(exon34) fusion, FGFR4 G388R, TP53 R280K 
10 SNU-2612A KIF5B(exon16)-RET(exon12) fusion 
11 SNU-2627 FGFR4 G388R 
12 SNU-2637 EML4(exon18)-ALK(exon20) fusion 
13 SNU-2641 PTPRD C1668* (targeted gene sequencing data) 
14 SNU-2643 EGFR exon19 deletion, FGFR4 G388R, TP53 R273C 
15 SNU-2657 BRAF V600E, ERRB2 I600V, FGFR4 G388R 
16 SNU-2681 ERBB2 I655V, KRAS G12C, TP53 R273C 
17 SNU-2689 EGFR L858R, ERBB2 I655V, FGFR4 G388R 
18 SNU-2693 PAK3 E480* (targeted gene sequencing data) 
19 SNU-2708.1 EGFR exon19 deletion 
20 SNU-2727 EGFR L858R 
21 SNU-2741 FGFR4 G388R, EGFR exon19 deletion 
22 SNU-2749 
BRAF V600E, ERBB2 I655V, TP53 Q331* nonsense mutation, FGFR4 
G388R 
23 SNU-2778 KIF5B(exon15)-RET(exon12) fusion, FGFR4 G388R 
24 SNU-2832 CD74(exon6)-ROS1(exon34) fusion, ERBB2 I655V 
25 SNU-2867 EGFR exon19 deletion 
26 SNU-2887 EGFR exon19 deletion 
27 SNU-2964 EGFR exon19 deletion 





Figure 9. Western blot analysis for EGFR, pERK1/2, ERK1, ERK2, 
PTEN, c-MET, Mesenchymal and Epithelial cell marker. 
Expressions of EGFR, pERK1/2, PTEN and c-MET in 28 lung cancer 
cell lines were analyzed by Western blot. The EGFR expression was 
elevated in our cell lines including SNU-2589, SNU-2606, SNU-2681, 
SNU-2693, SNU-2708.1, SNU-2727, SNU-2741, SNU-2867, SNU-
2887 and SNU-2964. Among the cell lines harboring EGFR L858R 
mutation (SNU-2689, SNU-2727 and SNU-3023), SNU-2727 
overexpressed the EGFR level. Furthermore, SNU-2708.1, SNU-2741, 
SNU-2867, SNU-2887 and SNU-2964 were amplified among the 7 cell 
lines exhibiting EGFR exon19 deletions (SNU-2556, SNU-2643, SNU-
2708.1, SNU-2741, SNU-2867, SNU-2887 and SNU-2964). Only 
SNU-2832 showed a high ERK1expression. ERK2 protein level was 
expressed generally significantly, whereas ERK2 expression in in SNU-
2585 was limited. Expression of phosphorylated ERK1 was generally 
pathetic in phosphorylated ERK1/2. Generally, the level of pERK2 was 
highly expressed. Especially pERK2 were extremely expressed in SNU-
2588, SNU-2657, SNU-2689, SNU-2689 and SNU-2708.1. PTEN 
expression was high in SNU-2867. c-MET expression level was overall 
weak except for SNU-3023. Vimentin expression levels were high in 
SNU-2550, SNU-2612A, SNU-2637, SNU-2657, SNU-2832 and SNU-
2887. N-cadherin expression was high in SNU-2612A. The expression 
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3.3. Anticancer drug response with mutational contexts 
The log EC50 values of the 27 lung cancer cell lines were estimated for 
erlotinib, gefitinib (tyrosine kinase inhibitors targeting EGFR), and 
crizotinib (anti-cancer drug targeting ALK and ROS1) (18,19). SNU-
2708.1 was excluded due to its slow growth rate. Quartiles were 
calculated to classify the established cell lines into relatively sensitive 
and resistant groups with respect to each drug. The results are 
summarized in Table 8. To confirm whether the mutational status of 
EGFR or ALK influenced the drug response of the newly-established 
lung cancer cell lines, widely used lung cancer cell lines harboring 
identical driver mutations were obtained. The NCI-H522 cell line has 
neither an EML4-ALK fusion nor a mutation in the EGFR kinase 
domain and was selected as a non-sensitive model for the drugs used. 
The HCC827 cell line was derived from a lung adenocarcinoma 
carrying a large deletion in the EGFR exon 19 (E746 - A750 deletion). 
Among the newly-established lung cancer cell lines, seven (SNU-2556, 
SNU-2643, SNU-2708.1, SNU-2741, SNU-2867, SNU-2887, and 
SNU-2964) harbored a large deletion in EGFR exon 19. As expected, 
the NCI-H522 cells didn’t respond to erlotinib compared to other cell 
lines, and HCC827 was notably sensitive to erlotinib compared to the 
newly-established lung cancer cell lines. To further inspect the 
mutational variations, the mutation data of NCI-H522 and HCC827 
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were obtained from the cancer cell line encyclopedia (CCLE) website 
(https://portals.broadinstitute.org/ccle). We extracted the CCLE genes 
from the WES data of the seven lung cancer cell lines and compared 
their mutational status with that of HCC827 (Figure 10, Table 9.). The 
average number of mutations found in the lung cancer cell lines was 
859, whereas the number of mutations in HCC827 was only 280. 
Moreover, stop gain mutations in the PDE4DIP, PRDM18, and DPYD 
genes were only present in the lung cancer cell lines, which may account 
for the resistance of the newly-established lung cancer cell lines (Table 
10).  
The NCI-H2228 cell line originated from a lung adenocarcinoma 
carrying an EML4 exon 6-ALK exon 20 fusion. Among the newly-
established lung cancer cell lines, five (SNU-2535, SNU-2550, SNU-
2553, SNU-2563, and SNU-2637) carried an EML4-ALK fusion. The 
NCI-H2228 cells exhibited a sensitive crizotinib response compared to 
other cell lines harboring an EML4-ALK fusion, except for SNU-2563 
which contained an EML4 exon 18-ALK exon 20 fusion (Figure 10, 
Table 9). The average number of CCLE gene mutations found in the 
lung cancer cell lines was 711, whereas the number of mutations in 
HCC827 was only 451. Accordingly, our cell lines which originated 
from a pleural effusion carried more mutations in the CCLE genes and 
were more resistant than those derived from primary lung cancer tissues. 
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Table 8. Drug sensitivity about gefitinib, erlotinib and crizotinib of 




(Log EC50, μM) 
Erlotinib  
(Log EC50, μM) 
Crizotinib  
(Log EC50, μM) 
1 SNU-2535 0.844±0.018 0.8±0.074 0.33±0.306 
2 SNU-2550 0.966±0.101 1.172±0.053 0.114±0.1 
3 SNU-2553 1.161±0.017 1.352±0.022 0.592±0.154 
4 SNU-2556 0.671±0.238 0.504±0.238 0.586±0.106 
5 SNU-2563 0.837±0.061 1.154±0.129 -1.343±0.382 
6 SNU-2585 1.035±0.076 0.642±0.268 0.611±0.345 
7 SNU-2588 0.501±0.145 0.658±0.048 0.509±0.095 
8 SNU-2589 1.208±0.084 1.462±0.067 0.707±0.21 
9 SNU-2606 0.749±0.168 0.938±0.038 0.477±0.17 
10 SNU-2612A 0.369±0.282 -0.246±0.091 1.107±0.132 
11 SNU-2627 1.05±0.023 0.962±0.038 -0.011±0.072 
12 SNU-2637 1.119±0.067 1.255±0.092 0.356±0.136 
13 SNU-2641 0.915±0.041 0.563±0.397 0.935±0.066 
14 SNU-2643 0.546±0.348 -0.086±0.122 0.969±0.028 
15 SNU-2657 1.251±0.134 0.911±0.266 0.805±0.252 
16 SNU-2681 1.012±0.054 1.096±0.052 0.587±0.076 
17 SNU-2689 0.799±0.079 1.033±0.027 1.048±0.089 
18 SNU-2693 0.796±0.371 0.841±0.276 0.49±0.093 
19 SNU-2708.1 - - - 
20 SNU-2727 1.786±0.199 1.067±0.23 1.29±0.031 
21 SNU-2741 1.123±0.132 0.976±0.399 0.911±0.2 
22 SNU-2749 0.833±0.057 0.707±0.07 0.554±0.043 
23 SNU-2778 0.718±0.018 0.676±0.025 0.585±0.022 
24 SNU-2832 0.906±0.181 1.042±0.306 -1.391±0.138 
25 SNU-2867 -0.034±0.573 0.079±0.262 0.768±0.158 
26 SNU-2887 0.928±0.147 0.922±0.205 0.794±0.21 
27 SNU-2964 0.959±0.064 0.931±0.032 0.643±0.038 















Figure 10. Drug sensitivity for erlotinib and crizotinib compared with 
other cell lines according to mutational traits.  
a. HCC827 showed the most sensitive erlotinib response compared with 
cells with a pleural effusion origin. Except for HCC827, SNU-2643 that 
carried EGFR exon19 homodeletion was most sensitive to erlotinib 
among our cell lines. In fact, NCI-H522 cells are the most resistant 
compared with cells that have EML4-ALK fusion, and deletion or 
mutation in EGFR kinase domain.  
b. NCI-H2228 cells were compared with our cell lines that carried 
EML4-ALK fusion. NCI-H2228 carry EML4 exon 6-ALK exon20 
fused gene. In the meantime, HCC827 cells were compared with our 
cell lines carrying a deletion in EGFR kinase domain. As a result, NCI-
H2228 cells showed a sensitive crizotinib response compared with other 
cell lines that exhibit EML4-ALK fusion except for SNU-2563 cell lines 
that harbor EML4 exon 18-ALK exon20.  
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Table 9. EC50 values of Erlotinib and Crizotinib, compared with other cell lines according to mutational traits 
  
Cell-Name Erlotinib (Log EC50, μM)  Cell-Name Crizotinib (Log EC50, μM) 
HCC827 -2.87±0.209  NCI-H2228 -0.211±0.076 
NCI-H522 1.598±0.119  NCI-H522 0.742±0.026 
SNU-2556 0.504±0.238  SNU-2535 0.33±0.306 
SNU-2643 -0.086±0.122  SNU-2550 0.114±0.1 
SNU-2741 0.976±0.399  SNU-2553 0.592±0.154 
SNU-2867 0.079±0.262  SNU-2563 -1.343±0.382 
SNU-2887 0.922±0.205  SNU-2637 0.356±0.136 
SNU-2964 0.930±0.032    
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Table 10. Common mutations in Erlotinib resistant lung cancer cell lines among EGFR exon 19 homodeletion cell lines 
Gene_Name CHROM POS REF ALT HGVS.c HGVS.p 
PDE4DIP chr1 144,852,390 C T c.7053G>A p.Trp2351* 
PDE4DIP chr1 145,075,683 C T c.180G>A p.Trp60* 
DPYD chr1 228,469,903 A T c.9754A>T p.Arg3252* 











3.4. Amplified DKK1 induces resistance to crizotinib 
We validated that cell lines derived from a pleural effusion exudate had 
more mutations and were resistant to targeted drugs compared to cell 
lines originating from tumor tissue. To evaluate the molecular 
alterations when cell lines which do not respond to targeted drugs 
acquire more resistance, we established two crizotinib-resistant sublines 
(SNU-2550CR and SNU-2563CR), derived from the parental SNU-
2550 and SNU-2563 cell lines by long-term exposure to increasing 
concentrations of crizotinib. Even though the SNU-2550 and SNU-2563 
cell lines harbored an EML4-ALK fusion, they were more resistant to 
crizotinib compared to NCI-H2228. The acquired resistance was 
confirmed by crizotinib treatment at varying concentrations (Figure 11a, 
11b). Epithelial-to-mesenchymal transition (EMT) has been previously 
observed in targeted drug-resistant lung cancer cells (20,21). Consistent 
with prior findings, morphological changes to the spindle-like cell 
shape were noted in both the SNU-2550CR and SNU-2563CR cells 
(Figure 11c). DKK1 has been previously reported to promote the 
migration and invasion of non-small cell lung cancer by inhibiting the 
phosphorylation of β-catenin (22,23). The elevated expression of DKK1 
was confirmed by both qRT-PCR (Figure 11d) and Western blotting 
(Figure11e). To further analyze if the secondary mutations in the 
crizotinib-resistant sublines affected their response to other drugs, eight 
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lung cancer drugs approved by the National Cancer Institute (NCI) and 
one chemical compound which inhibits the canonical Wnt pathway 
were used to treat the crizotinib-resistant sublines, along with the cell 
lines carrying an EGFR exon 19 deletion and an EML4-ALK fusion. 
The cell lines carrying an EGFR exon 19 deletion and an EML4-ALK 
fusion were clustered into different groups. Although the crizotinib-
resistant sublines clustered with the EML4-ALK groups, they showed 
cross-resistance to both ceritinib and alectinib (a second-generation 
ALK inhibitor) and trametinib (MEK inhibitor) (Figure 11f). 
Interestingly, the SNU-2563CR subline exhibited resistance to all tested 
drugs. To further analyze the molecular alteration of the crizotinib-
resistant sublines, WES and RNA sequencing (RNA-seq) were 
performed on both parental and crizotinib-resistant sublines. WES 
revealed a novel nonsense mutation in the PRSS1 gene in both 
crizotinib-resistant sublines. A germline mutation in PRSS1 has been 
associated with hereditary pancreatitis and  familial pancreatic cancer 
(24), yet its function in crizotinib resistance has not been elucidated. 
SPIA two-way analysis was performed on the RNA-seq to pinpoint the 
aberrant pathways. Aberrant focal adhesion signaling was found in both 
crizotinib-resistant sublines (Figure 12a, b). Among the various genes 
involved in focal adhesion signaling, the mRNA expression of the 
Dickkopf-related protein 1 (DKK1) was significantly increased in both 
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crizotinib-resistant sublines (Figure 11d). We further investigated the 
potential role of amplified DKK1 expression in crizotinib-resistance by 
immunocytochemistry (ICC). ICC indicated that the nuclear 
localization of β-catenin was significantly increased in both crizotinib-
resistant cell lines (Figure 11b, 11c). Accordingly, these results indicate 
that the EMT-derived crizotinib resistance was accompanied by 
augmented DKK1 expression. In conclusion, we have established 28 
NSCLC cell lines from a malignant pleural effusion and associated their 
mutational traits with targeted drug responses. The cell lines were 
relatively resistant compared to cell lines originating from other tissues 
exhibiting similar mutational features. We also established two 
crizotinib-resistant sublines from cell lines carrying an EML4-ALK 
fusion gene. Comprehensive molecular analysis revealed that a novel 
nonsense mutation in the PRSS1 gene was present in the crizotinib-
resistant sublines and that the expression of DKK1 was significantly 
augmented in the crizotinib-resistant sublines. Such analyses facilitate 








Figure 11. Establishment of two crizotinib resistant sublines. a, b. The 
acquired resistance was confirmed with crizotinib treatment in various 
concentrations. c. Morphological changes to the spindle-like cell shape 
were noted in both SNU-2550CR and SNU-2563CR cells. d. The mRNA 
expression of DKK1 was augmented in crizotinib resistant sublines. e. 
The protein expression of EMT-related genes and DKK1. e. Drug 
treatment of two crizotinib resistant sublines along with cell lines that 






Figure 12. Molecular analysis of crizotinib resistant sublines a, b. SPIA 
analysis indicating aberrated pathways of two crizotinib resistant 
sublines. c, d. Nuclear localization of beta-catenin is significantly 























Lung cancer is main cause of death related to cancer. However, 
diagnosis remained poor except for some specific mutation target-
drugs.(3,17) There are various mutations accounting for development 
of lung cancer, and some cases are not explained with known causes. 
Lung cancer is the most lethal disease and 3rd common cancer in 
Korea.(2) Especially, our 28 lung cancer cell lines were originated from 
lung pleural effusion exudate not from tissue directly. Migrated cancer 
cells indicate that cancer cells in lung tissues break out into pleural 
cavity and lung tissues are no longer normal. Pleural effusion in patients 
with NSCLC (Non-small cell lung carcinoma) is known to have 
prognostic value.(5) Therefore, the mutational status of established lung 
cancer cell lines derived from pleural effusion exudate is accorded to 
the drug response of the cell lines.  
NSCLC is about 85% of all lung cancer.(1) As mentioned earlier, 
mutations in epidermal growth factor receptor (EGFR) or anaplastic 
lymphoma kinase (ALK) fusion with other domain is related to high 
probability of NSCLC (non-small-cell lung carcinoma) risk.(4,7,13) 
Variations of EGFR are well-known driver mutations. Overexpression 
of EGFR takes 6% of NSCLC and mutations in tyrosine kinase domain 
are occupying up to 15%.(4) EGFR exon19 deletion are also occupying 
about 10% in USA and 35% in Asia.(4,25,26) Because of high 
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proportion of EGFR mutations in NSCLC, detection of mutated EGFR 
genes and its protein expression level is examined in recent studies. In 
ERBB family, overexpression of ERBB2 also takes about 6% and 
mutations in tyrosine kinase domain take 5%.(27,28) Gene 
translocation of ALK that is frequently fused with EML4 is also well-
known mutation of NSCLC. Those rearrangements occupy about 5% of 
total NSCLC causes. In addition, KRAS and BRAF also are more usual 
in smokers’ cases and develop resistance tyrosine kinase inhibitors 
associated EGFR. In NSCLC, mutations of KRAS and BRAF occupy 
5-15% and 2% each.(29-31)  
Patients who have mutations mentioned above are treated with tyrosine 
kinase inhibitor such as Erlotinib and Gefitinib. Those patients are also 
treated with Crizotinib in case of harboring fusion gene like ALK 
rearrangement.(18,32,33) Crizotinib also targets proto-oncogene 
tyrosine-protein kinase ROS encoded by ROS1 gene and MET, so 
called hepatocyte growth factor receptor (HGFR) encoded by MET 
gene.(33,34) NSCLC have been found in harboring driver mutations 
continuously. Driver mutations in our cell lines were detected and 
validated. First of all, fusion gene detection was conducted with RT-
PCR. It is occasional that NSCLC has Anaplastic lymphoma kinase 
(ALK) gene rearrangement with other gene.(35) Besides ALK fusion is 
tend to be found in all ages.(1) In 28 lung cancer cell lines, SNU-2535, 
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SNU-2550, SNU-2553, SNU-2563 and SNU-2637 have EML4-ALK 
fusion. EML4-ALK fusion is not to be found in lung tumors that have 
EGFR or KRAS mutation.(36) Actually SNU-2535, SNU-2550, SNU-
2553, SNU-2563 and SNU-2637 don’t have pathogenic mutation of 
EGFR or KRAS, and they have effectively increased sensitivity to 
Crizotinib, ALK target inhibitor according to drug test. Especially, 
SNU-2563 has ALK gene fusion with relatively infrequent EML4 18th 
exon, and it is very sensitive to Crizotinib. In our cell lines, SNU-2535 
has G1269A mutation in ALK. G1269A mutation located in ALK 
kinase region induce Crizotinib resistance.(37), and SNU-2535 was the 
most resistant to Crizotinib in cells harboring ALK rearrangement. 
Recently, G1269A mutation in ALK kinase domain is treated by 
specific target-drug, Alectinib.(38) ALK amplification are frequent in 
lung cancer cells with rearrangement of ALK genes, and they are 
sensitive to ALK inhibitors.(39) The mRNA level of ALK in SNU-2563, 
SNU-2589 and SNU-2637 were highly overexpressed. They were 
sensitive to ALK inhibitor despite SNU-2589 don’t have EML4-ALK 
fusion. This may imply the amplified ALK expression is responsible for 
sensitivity of ALK inhibitors even without EML4-ALK fusion. SNU-
2563 was the most sensitive to ALK inhibitor and other ALK 
overexpressed cell lines also have sensitive characteristics on Crizotinib. 
Other Crizotinib target, ROS1 is also receptor tyrosine kinase. ROS1 
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fusion have increased sensitivity to Crizotinib likewise EML4-ALK 
fusion.(1) In our cell lines, SNU-2606, SNU-2832 was found to have 
CD74-ROS1 fusion. Actually SNU-2606 and SNU-2832 were sensitive 
to Crizotinib. SNU-2553, SNU-2589, SNU-2606, SNU-2637 and SNU-
2832 had high mRNA expression level in RT-PCR targeting the ROS1 
kinase domain. Generally, CD74-ROS1 fusion doesn’t co-exist with 
ALK fusion as well as pathogenic EGFR or KRAS mutation.(40) 
KIF5B-RET fusion is also well known gene rearrangement in 
NSCLC.(12) SNU-2612A and SNU-2778 have KIF5B-RET fusion 
gene. Relative to ALK fusions, KIF5B-RET fusion is less frequent. 
Although SNU-2612A was sensitive group to Gefitinib as well as 
Erlotinib, KIF5B-RET fusion generally has no distinguished 
characteristics about Erlotinib, Gefitinib and Crizotinb. Vandetanib is 
generally used to target KIF5B-RET fusion.(41) We suggest that SNU-
2612A and SNU-2778 are sensitive to RET rearrangement targeting 
drug like Vandetanib.  
EGFR mutations as well as fusion genes are important factors of lung 
cancer.(36) Representative mutational regions of EGFR are exon 18-20 
regions in which EGFR kinase domain exists. Especially, EGFR exon 
19 deletion as well as rearrangement of gene like ALK, ROS1 and RET 
are important characteristics of lung cancer.(42) Lung adenocarcinoma 
cell lines that have EGFR exon 19 deletion are generally sensitive to 
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Gefitinib and Erlotinib.(43) In our 28 lung adenocarcinoma cell lines, 
total 7 cells (SNU-2556, SNU-2643, SNU-2708.1, SNU-2741, SNU-
2867, SNU-2887, and SNU-2964) had EGFR deletion in exon 19. SNU-
2556, SNU-2887 and SNU-2964 that had EGFR deletion in E746-A750 
weren’t relatively sensitive in our cell lines. Interestingly, SNU-2643 
had homo-deletion in EGFR exon 19, logEC50 of SNU-2643 was highly 
sensitive to Gefitinib and Erlotinib compared to other cell lines that 
have EGFR exon 19 hetero-deletion. Except for SNU-2708.1 that had 
slow growth rate, SNU-2741 that had deletion in L747-T751 weren’t 
sensitive, neither. Though SNU-2741 had additional deletion at 753th 
amino acid, it didn’t present high sensitivity. Rather SNU-2741 was the 
most resistant cell lines to Gefitinib among 7 lung cancer cell lines that 
had EGFR exon19 deletion. SNU-2867 had L747-S752 deletion of 
amino acid as well as E746V substitution. 20 nucleotides were largely 
deleted. SNU-2867 that had these variation was the most sensitive to 
Gefitinib and highly sensitive to Erlotinib, too. SNU-2741 also had 
large deletions but was the most resistant cell lines to Gefitinib of 7 lung 
cancer cell lines. Genomic location of deleted sequences might be more 
important to drug response than the number of deletion amino acid. Our 
cell lines were tended to have resistance to TKI although there are 
relatively sensitive or resistant in our cell lines obtained from pleural 
effusion exudate. Except for EGFR T790M mutation, acquired 
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resistance mechanism about TKI is not well-known and these target 
drugs also are not verified. If cell lines that acquired resistance to TKI 
because of T790M mutation in EGFR, Osimertinib is recently 
treated.(44,45) Nevertheless, our cell lines that harbor EGFR deletion 
or mutation don’t have T790M mutation in EGFR. Further study for 
various TKI resistance mechanism and overcoming resistance is 
suggested. The results for mutation analysis for driver mutations 
(BRAF, EGFR, ERBB2, FGFR4, KRAS and TP53) were paralleled to 
the drug-response data. Cells that have somatic mutations of EGFR 
c.2602T>G (p. L858R) variation are also generally sensitive to 
Gefitinib and Erlotinib. (25,43) SNU-2689, SNU-2727 and SNU-3023 
had L858R mutation and they were sensitive to Gefitinib and Erlotinib 
except for SNU-2727. Even though SNU-2727 has EGFR L858R 
substitution, it was resistant to TKIs without T790M missense mutation. 
This may imply that SNU-2727 develop acquired resistance. SNU-3023 
was sensitive to drug treated. In contrary to EGFR deletion or L858R 
mutation, cells that have KRAS 12th amino acid Glycine variation 
decreased sensitivity to TKI.(29) SNU-2585 have G12V variation and 
SNU-2681 had G12C variation. In Erlotinib treatment, SNU-2585 was 
exceptionally sensitive. Of the remaining cell lines, there are no clear 
evidence to sensitivity targeting to TKI. Even if lung cancer cells that 
have resistance to EGFR inhibitors like Erlotinib sporadically harbor 
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BRAF mutations, and this is not shown in our cell lines.(30) SNU-2657 
and SNU-2749 harbored c.1799T>A (p.V600E) variation, but there 
were no special patterns to TKI. Other interesting point in those cell 
lines was that they all had c.1963A>G (p. I655V) mutations in ERBB2 
gene. I655V variation in ERBB2 is well-known as pathogenic driver 
mutation in breast cancer.(46,47) In our analysis for driver mutations, 
the cells that had I655V variation were genetically instable. Those cells 
had many other mutations like nonsense mutations in TP53 genes. 
I655V variation in ERBB2 might be used as lung cancer prognosis 
marker for Asian. Furthermore, we suggest that harboring V600E 
variation in BRAF might be marker for I655V mutation in Asian. 
G388R polymorphism in FGFR4 also could be potential indicator for 
clinical stage in Asian. In Italian lung adenocarcinoma cases, survival 
of patients with G388R allele significantly decreased.(48) G388R 
polymorphism in FGFR4 can expect prognosis in lung 
adenocarcinoma.(49) In fact, 12 cells (SNU-2535, SNU-2556, SNU-
2588, SNU-2606, SNU-2627, SNU-2643, SNU-2657, SNU-2689, 
SNU-2741, SNU-2749, SNU-2778 and SNU-3023) of total 28 cells 
harbored G388R mutation in FGFR4. Half of our cell lines that were 
originated from pleural effusion had G388R mutation could indicate 
that G388R mutation in FGFR4 might be marking highly progressed 
stage in lung cancer with pleural effusion. 
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In protein expression level, overexpression or decreased expression of 
specific oncoproteins like ERK, ERBB2, c-MET and PTEN can affect 
to cancerous features. pERK1/2 is commonly activated in NSCLC and 
associated with progressive cancers.(50) pERK1/2 were highly 
expressed in SNU-2588, SNU-2657, SNU-2689, SNU-2689 and SNU-
2708.1. In our cell lines, ERK1/2 was activated in about 70% cell lines. 
Such results support that ERK1/2 activation indicating progressive 
status is applied to Korean cases. Representative cancer repressor, 
PTEN expression level is important to understand characteristics of cell 
lines. PTEN loss or reduced PTEN expression level affect to TKI 
sensitivity.(51,52) PTEN expression of SNU-2689, SNU-2693 and 
SNU-2727 was reduced. Those cell lines were not sensitive to Erlotinib. 
SNU-2693 was resistant group but, these results didn’t correspond with 
Gefitinib. SNU-2693 was sensitive to Gefitinib. Generally, increased 
copy number or overexpression of c-MET induce resistance to Gefitinib 
in non-small cell lung cancer.(53,54) Because Crizotinib also targets 
MET, cells that have increased expression of MET are generally 
sensitive to Crizotinib.(33) SNU-3023 had overexpressed c-MET level 
in our western blot results. SNU-3023 was sensitive to all drugs that 
were treated. About characteristics resisting against TKI, SNU-3023 
was not matched. We assumed that these features were affected by 




Comparison of drug sensitivity with other cell lines according to 
mutational traits could be important because cancer cell lines in pleural 
effusion are relatively resistant compared with cell lines originated from 
lung cancer tissue. HCC827 had the most sensitive Erlotinib response 
compared with cells that have pleural effusion origin. Except for 
HCC827, SNU-2643 that has EGFR exon19 homo-deletion is most 
sensitive to Erlotinib among our cell lines. And NCI-H2228 cells had 
sensitive Crizotinib response compared with other cell lines that have 
EML4-ALK fusion except for SNU-2563 that have EML4 exon18-
ALK exon20. Such considerable difference between pleural effusion 
origin and tissue origin could suggest that needs for other approach to 
treat of anti-cancer drugs in lung cancer. It might be significant that 
cancer cells from pleural effusion have progressive status and malignant 
features.(5,6)  
We also established a crizotinib-resistant subline (SNU-2550CR and 
SNU-2563CR), which was derived from the parental SNU-2550 and 
SNU-2563 cell lines by long-term exposure to increasing 
concentrations of crizotinib. Characteristics associated with EMT 
including morphology, EMT marker proteins, and cellular mobility, 
were analyzed. Compared with parental cells, the growth of crizotinib-
resistant subline cells was independent of EML4-ALK, and crizotinib-
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resistant subline cells showed cross-resistance to both ceritinib and 
alectinib (a second-generation ALK inhibitor). An ALK inhibitor is the 
standard treatment for advanced non–small cell lung cancer (NSCLC) 
patients harboring the anaplastic lymphoma kinase (ALK) fusion gene. 
However, secondary ALK mutations or alternative pathway changes 
cause a fraction of the tumors to be resistant to ALK inhibitors (10,11). 
We validated that cell lines derived from a pleural effusion exudate had 
more mutations and were resistant to targeted drugs compared to cell 
lines originating from tumor tissue. To evaluate the molecular 
alterations when cell lines which do not respond to targeted drugs 
acquire more resistance, we established two crizotinib-resistant sublines 
(SNU-2550CR and SNU-2563CR), derived from the parental SNU-
2550 and SNU-2563 cell lines by long-term exposure to increasing 
concentrations of crizotinib. Even though the SNU-2550 and SNU-2563 
cell lines harbored an EML4-ALK fusion, they were more resistant to 
crizotinib compared to NCI-H2228. The acquired resistance was 
confirmed by crizotinib treatment at varying concentrations (Fig 7a, 7b). 
Aberrant focal adhesion signaling was found in both crizotinib-resistant 
sublines. Among the various genes involved in focal adhesion signaling, 
the mRNA expression of the Dickkopf-related protein 1 (DKK1) was 
significantly increased in both crizotinib-resistant sublines. DKK1 has 
been previously reported to promote the migration and invasion of non-
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small cell lung cancer by inhibiting the phosphorylation of β-catenin 
(27,28). The elevated expression of DKK1 was confirmed by both qRT-
PCR (Fig 7d) and Western blotting (Fig 7e). We further investigated the 
potential role of amplified DKK1 expression in crizotinib-resistance by 
immunocytochemistry (ICC). ICC indicated that the nuclear 
localization of β-catenin was significantly increased in both crizotinib-
resistant cell lines (Fig 8b, 8c). Accordingly, these results indicate that 
the EMT-derived crizotinib resistance was accompanied by augmented 
DKK1 expression. Comprehensive molecular analysis revealed that a 
novel nonsense mutation in the PRSS1 gene was present in the 
crizotinib-resistant sublines and that the expression of DKK1 was 
significantly augmented in the crizotinib-resistant sublines. 
In conclusion, we have established 28 NSCLC cell lines from a 
malignant pleural effusion and associated their mutational traits with 
targeted drug responses. The cell lines were relatively resistant 
compared to cell lines originating from other tissues exhibiting similar 
mutational features. We also established two crizotinib-resistant 
sublines from cell lines carrying an EML4-ALK fusion gene. Such 
analyses facilitate studies associated with drug treatment and 
representative mutations. Those results could mean that cancer cells in 
pleural effusion exudate might be group of harboring more malignant 
population than group of sustaining in tissue, and that could affect drug 
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sensitivity. We focused on that established cell lines gathered from 
pleural effusion is resistant to target drug and those cell’s information 
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폐암은 흔한 종류의 암이나 진단 방법은 여전히 미비하다. 
최근 서양에서는 폐암 발병률이 감소한 반면에 아시아에서는 
폐암 발병률이 전반적으로 증가하고 있다. Caucasian type 에 
비해 Asian type 의 돌연변이 패턴을 조사한 연구는 참고할 
만한 적절한 자원이 부족하다. 특히 흉수에서 암세포를 얻어 
수립된 폐암 세포주는 세포주 모델에서는 상대적으로 드문 
경우이다. 비소 세포 폐암 환자의 흉수로 전이된 암세포는 그 
진행이 빠르며 악성 종양의 경향을 보이는 경우가 많다. 본 
연구에서는 28 개의 흉수 유래 폐암 세포주를 새로이 
확립하여 세포 및 분자생물학적 특성을 분석 하였다. BRAF, 
EGFR, ERBB2, FGFR4, KRAS 및 TP53의 대표적인 돌연변이 및 
ALK, CD74 및 RET 유전자와 같은 fusion gene 이 검출되고 
확인되었다. 세포주가 가진 대표적인 돌연변이에 따라 gefitinib, 
erlotinib and crizotinib 에 대한 약물 감수성을 측정 하였다. 각 
약물에 표적 돌연변이를 갖는 세포주는 일반적으로 표적 
약물에 민감하게 반응하였다. 흉수 유래의 세포주는 유사한 
돌연변이가 있는 조직 유래의 세포주보다 상대적으로 내성이 
있는 경향을 보였다. 이러한 세포주의 돌연변이 패턴 및 약물 
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감수성 분석은 여러 사례가 누적된 데이터베이스 구축을 
돕는다. 또한 ERK, ERBB2, c-MET 및 PTEN 과 같은 특정 
oncoprotein 의 발현 정도를 수립한 세포주에서 관찰하였다. 
마찬가지로 EpCAM, E-cadherin, N-cadherin 및 Vimentin 과 같은 
EMT marker 도 관찰하였다. 흉수에서 유래된 28 종의 폐암 
세포주는 항암제 감수성 및 폐암에서 대표적인 돌연변이와 
관련된 연구를 뒷받침하도록 돕는다. 현재까지도 crizotinib 에 
대한 저항성에 대한 사례는 여전히 제한적이다. 이러한 
요구를 충족시키기 위해서 우리는 crizotinib 내성 세포주를 
확립했다. 그들의 유래 세포주는 EML4-ALK fusion gene 을 
보유한 세포주 였으며 우리가 수립한 세포주들 안에서는 
상대적으로 crizotinib 에 민감하였으나. 내성이 유도된 후 
민감하게 반응하지 않게 되었다. 우리는 그들의 특성과 내성 
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